Sort   by:  
 Page size 
ProteomicsProteomic profiling of PRLX-93936 and structurally similar compounds in pancreatic cancer cells. 
To determine the downstream molecular mechanism of PRLX-93936, we performed systematic proteomic profiling of cells treated with PRLX-93936, erastin, or JWZ-8-103. Results include global proteome profiling, ubiquitylation proteomics, and proximity labeling proteomics enabling comparison of drug-indu...
ORGANISM(S): Homo sapiens (Human) 
2025-08-15 | PXD059137 | Pride
Proximity labeling proteomics Pancreatic cancer Global proteome profiling Panc-1 cells Lfq Diapasef Ubiquitylation proteomics 
UnknownDevelopment of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.
Not available
S-EPMC4260976 | biostudies-literature
UnknownDefining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.
Not available
S-EPMC12670082 | biostudies-literature
UnknownImpact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Not available
S-EPMC4574015 | biostudies-literature
GenomicsAlzheimer's Disease Sequencing Project (ADSP)

The overarching goals of the ADSP are to: (1) identify new genomic variants contributing to increased risk of developing AD, (2) identify new genomic variants contributing to protection against developing AD, and (3) provide insight as to why individuals with known risk factor variants escape fro...

phs000572.v1.p1 | EGA
UnknownClonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Not available
S-EPMC4472749 | biostudies-literature
UnknownOlder patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Not available
S-EPMC4050299 | biostudies-literature
Sort   by:  
 Page size